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The prevalence of diabetic retinopathy in Faisalabad, Pakistan:
a population-based study
Fatma HUSSAIN1, Mohammad ARIF2, Munir AHMAD1

Aim: To determine the plasma prevalence and characteristics of diabetic retinopathy (DR) among Pakistani diabetic
patients in the Faisalabad region. Diabetes mellitus (DM) is a major cause of avoidable blindness worldwide. People with
DR are 25 times more likely to become blind than nondiabetics.
Materials and methods: The incidence of retinopathy was determined in 1524 people with diabetes during April 2008
and January 2009. Physician-diagnosed diabetic patients underwent an eye examination by ophthalmoscopy and fundus
photography. Participants were also interviewed and examined in order to determine demographic characteristics and
medical history.
Results: Of the 1524 patients screened, 183 (12%) had DR. Of these, 7% (106) had nonproliferative DR and 5% (77)
had proliferative DR. Clinically significant macular edema was detected in 1.2% of patients. The prevalence of DR was
higher in patients with type 1 diabetes than in those with type 2 diabetes. This difference was found to be statistically
insignificant, however (P > 0.05). About 3% of the diabetic patients in our study had a family history of diabetes and only
6% had a history of regular eye examinations.
Conclusion: This study demonstrated a high prevalence of DR in Faisalabad. An organized approach is needed to
ensure adequate prevention and treatment in patients with diabetes.
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Introduction
Retinopathy, a potentially devastating microvascular complication in diabetes mellitus (DM),
is a leading cause of acquired blindness. Diabetic retinopathy (DR) is known best in terms of
epidemiology and natural history. Diabetic patients are 5 times more likely to experience a loss
of vision than nondiabetics. Nearly 80% of the type 2 diabetic population experiences earlier
clinical signs of DR. Patients with poor long-term glycemic control are more vulnerable to DR
than to other secondary sequels of diabetes (1-3). Factors such as the duration of diabetes, age,
gender, and glycemic control are associated with the development and progression of DR (3,4).
The best empirical tool available to clinicians trying to delay the onset and progression of diabetic
retinopathy is achieving near-normal levels of blood glucose (1). Nonetheless, DR remains a
frightening prospect for patients and frustrates physicians.
In 2003, 6.2 million Pakistani people had diabetes, a number that is expected to reach 11.6
million by 2025. By then, Pakistan will rank fourth among countries most affected by diabetes
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(5). In Pakistan, reports project that casualties from
diabetes will rise to 51% over the next 10 years.
The growth of such an epidemic disease definitely
burdens the economics of public and private sector
health plans (6). Faisalabad is the third largest city in
Pakistan, with an estimated population of 4 million.
Existing studies (7-14) on DR prevalence are lacking
in data from this area. This population-based study
was therefore performed in order to determine the
DR prevalence and clinical characteristics of the
disease in the Faisalabad region.
Materials and methods
The incidence of retinopathy was determined in
1524 people with diabetes during April 2008 and
January 2009. Before recruitment, ethical approval
was granted by the institution’s Advanced Studies and
Research Board. The inclusion criteria for recruitment
were based on disease duration (candidates should
have been living with diabetes for more than 1 year)
and age (candidates had to be between 20 and 70
years of age).
Our investigation was performed by 1 physician
and 2 ophthalmologists who were experienced
in treating DM and DR. After informed written
consent, participants were interviewed and
examined to determine their demographic, clinical
characteristics, and medical history. Medical
history included all medical conditions that had
been and were presently being treated. Patient care
was documented, from the first practitioner to the
specialist. Baseline demographic characteristics
such as age, gender, type of diabetes, and diabetes
duration were also documented. A detailed
ophthalmic examination was given, which included
visual acuity, slit-lamp biomicroscopy, intraocular
pressure, gonioscopy, dilated funduscopy including
stereoscopic examination of the posterior pole, and
an examination of the peripheral retina and vitreous
(15,16).
Initial retinal examinations are recommended
for patients with type 1 diabetes 3-5 years after
diagnosis and for type 2 diabetes patients at the time
of diagnosis. Follow-up screenings for both types
of DM should be performed annually, although
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abnormal findings may necessitate more frequent eye
examinations (17,18). All of our participants were
examined only once, at the start of the study, but they
were informed about the recommended examination
schedule.
Retinopathy was diagnosed using direct and
indirect ophthalmoscopy, with results divided into 2
categories, nonproliferative (NPDR) and proliferative
diabetic retinopathy (PDR). The criteria for each
category were as follows.
NPDR: Presence of microaneurysms (less than in
severe NPDR); the presence of any of the following:
>20 intraretinal hemorrhages in each of the 4
quadrants, definite venous beading in 2+ quadrants,
prominent intraretinal microvascular abnormalities
in 1+ quadrant, and no signs of proliferative
retinopathy.
PDR: Presence of one or more indicators of
neovascularization, vitreous/preretinal hemorrhage,
or diabetic macular edema (DME). DME was
identified by apparent retinal thickening or hard
exudates in the posterior pole, retinal thickening or
hard exudates in the posterior pole but distant from
the center of the macula, retinal thickening or hard
exudates approaching but not involving the center
of the macula, or retinal thickening or hard exudates
involving the center of the macula (18,19).
For the biochemical assay, 5-mL blood samples
were collected in EDTA-coated tubes from all study
participants. Blood plasma samples, separated by
centrifugation at 4500 rpm for 20 min, were stored
in vials at –20 °C until further analysis was possible.
Postprandial glucose and A1c were measured
with a glucose oxidase and A1c kit (Biosystem,
Spain). The thiobarbituric acid (TBA) colorimetric
technique was used for the determination of plasma
protein nonenzymatic glycation (NEG) (20). All
measurements were performed in triplicate in our
clinical-medical biochemistry laboratory with
adherence to quality control procedures. Descriptive
statistics were expressed as a number (n), a mean ±
SD, or a percentage (%) ± SD, as appropriate. For
analytic purposes, the chi-square test was utilized
with SPSS 14 with the level of significance set at P ≤
0.05.
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Results

Little research has been performed on the incidence
of DR and its clinical characteristics among the
Pakistani population. To our knowledge, none of the
previous studies from Pakistan (7-14) describe the
incidence of DR in Faisalabad.

Baseline demographic and clinical characteristics
of the participants are outlined in the Table. Case
participants were further stratified into 3 groups:
diabetic patients with NPDR, diabetic patients with
PDR, and diabetic patients without DR. Of the 1524
patients examined, 183 (12%) had DR. Of these, 7%
and 5% had nonproliferative DR and proliferative DR,
respectively. Clinically significant macular edema
was detected in 1.2% of patients. The prevalence
of DR was higher in type 1 diabetes patients when
compared to type 2 diabetics. About 3% of our
diabetic patients had a family history of diabetes and
only 6% had a history of regular eye examination.
Differences in mean postprandial glucose, HbA1c,
total proteins, and NEG levels among the 3 groups
were insignificant (P > 0.05).

The current study demonstrates that the
prevalence of DR was 12% in a representative sample
of diabetic patients in Faisalabad, Pakistan in 20082009. This prevalence is analogous to the rates
previously reported (15% to 19.9%) in the literature
(14,21-24).
A study of chronic complications by the Diabetic
Association of Pakistan (8) reported that eye damage
(retinopathy) affected 43% of the 500 diabetic patients
examined. Pilot studies performed by Kayani et al.
(9) and by Khan (10) suggested a higher prevalence
of DR (26.1% and 33.3%) among diabetic Pakistanis.
Wong et al. observed a 35% prevalence of DR in
Singapore (25), while Ossama et al. observed a 42.4%
DR incidence among the Omani population (26).
Regarding the prevalence of NPDR (7%) and PDR
(5%) observed in our study, ambiguous results exist

Discussion
Retinopathy,
a
potentially
devastating
microvascular complication that occurs with
diabetes, is a leading cause of acquired blindness.

Table. Baseline demographic and clinical characteristics of 1524 diabetic participants.
Diabetic Patients with
NPDR

Diabetic Patients
with PDR

Diabetic Patients
without DR

106

77

1341

Sex (male/female)

65/41

43/34

833/508

Diabetes type (1/2)

62/44

45/32

714/627

8.3 ± 2.41

9.66 ± 1.31

8.1 ± 2.92

17

10

15

47

15

11.78 ± 1.36

12.4 ± 2.41

11.44 ± 1.89

11 ± 0.5

10 ± 1.1

10 ± 0.87

Total plasma proteins (g/dL)

12.89 ± 0.75

13.61 ± 1.7

13.01 ± 1.97

NEG (mol/mol)

1.27 ± 0.55

1.35 ± 0.35

1.33 ± 0.77

Characteristics
Diabetic subjects (n)

Diabetes duration (years)
Family history of diabetes (n)
History of regular eye examination (n)
Glucose (mmol/L)
HbA1c (%)

29

Data as number (n), mean ± SD, or percentage (%) ± SD
NPDR: Nonproliferative diabetic retinopathy, PDR: proliferative diabetic retinopathy, NEG: nonenzymatic
glycation
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in the literature. Among Omani diabetics, NPDR and
PDR were discovered in 4% and 12.8% patients (26).
In contrast, 2 studies from Shanghai indicated 19.4%21.6% and 0.5%-1.3% prevalence of NPDR and PDR,
respectively (24,27). The comparison of prevalence
rates using different methodologies requires caution.
In the multiethnic population of Mauritius, the
prevalence of NPDR and PDR was 42% and 2.3%,
respectively, among known diabetics (28). Collins et
al. observed a 38.7% and 4.5% incidence of NPDR
and PDR in the Polynesian population (29). The
Wisconsin Epidemiologic Study of DR indicated
prevalence rates of 35.5% for NPDR and 2.9% for
PDR in Caucasians (2). A direct comparison of rates
between studies indicates variation in prevalence
among various ethnic groups. Haffner et al. proposed
that insulin resistance might explain these apparent
differences (30).
In our study, the prevalence of DR was higher
in type 1 diabetic patients when compared with
type 2 diabetics. Hietala et al. (31) found a familial
clustering of proliferative retinopathy in patients with
type 1 diabetes. This observation suggests a genetic
component in the pathogenesis of proliferative
retinopathy in type 1 diabetes. After living with
diabetes for 20 years, nearly all patients with type
1 diabetes were found to have some degree of
retinopathy (32). Type 2 diabetes involves islet
dysfunction and insulin resistance, which may
improve with treatment. Type 2 diabetes is often
associated with genetic and environmental factors,
but the nature of the interactions is complex and not
clearly defined (33,34). Such factors may justify the
high prevalence of DR among type 1 diabetic patients
found in our study.
Contrary to these observations, several studies
(35-37) suggest the presence of retinopathy
and proteinuria (indicating renal damage) in
approximately one-third of type 2 diabetics at the time
of diagnosis. Generally, patients have type 2 diabetes
mellitus for about a decade before the diagnosis is
made, and it is estimated that about half of the cases
are undiagnosed (38). A direct association between
retinopathy and diabetes duration has been shown to
exist (39). Variations in average diabetes duration was
not found to be significant (P > 0.05) among diabetics
with NPDR, PDR, and those without DR, and the
738

established male preponderance in DR prevalence
(21,40) was not shown by our study population. A
consistent gender pattern in the DR prevalence of the
Faisalabad region (P > 0.05) is supported by another
study (25). Genetic predisposition to DR (41) was
also not prominent in our data analysis, as only 3% of
patients had a family history of DR.
The precise relevance of postprandial glucose
is not exactly comprehensible or quantifiable in
DM. Evidence shows that, after mean daily blood
glucose, the postprandial glucose level is the major
determinant of the HbA1c level (42-45), and a
reduction in postprandial hyperglycemia significantly
reduces the HbA1c level in diabetics. Postprandial
excursions of blood glucose may be involved in the
development of diabetes complications (46-48).
In our research, the difference in postprandial
blood glucose levels among diabetic subjects with
NPDR, those with PDR, and those who showed
no signs of DR was determined to be insignificant.
Elevated 2-h plasma glucose measurements (16.6
mmol/L) among diabetics with retinopathy were
observed by Dowse et al (28).
Many lines of evidence attest to the fact that the
direct deleterious action of glucose and other sugars
on proteins, known as glycation or the nonenzymatic
glycosylation process, attenuates the development
of a range of diabetes-related complications.
Postprandial glucose levels were measured because
intensive blood glucose monitoring during both
fasting and postprandial states is important for
glycemic control (49). Postprandial glucose and
HbA1c were analogous (P > 0.05) among diabetics
with NPDR, those with PDR, and those with no such
ocular complications. Effective glycemic control has
been demonstrated to reduce both the incidence and
progression of DR (50,51).
The nonsignificant difference in blood glucose
and HbA1c values among all 3 study groups may be
due the fact that plasma hemoglobin A1c (HbA1c)
reflects ambient mean glycemia over a period of 2 to
3 months (51). Although glycemic goals should be
individualized based on several clinical factors, most
diabetic patients would probably benefit from glucose
being lowered to a hemoglobin A1c level between 7%
and 8% (52). Factors such as disease severity, health
status, and poorer quality of care are often associated
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with differences in glycemic levels, but these factors
did not fully explain the higher HbA1c levels in all
races (53,54).
Metabolic derangements lead to a breaking down
of tissue protein in DM. Anabolic processes like
protein synthesis are sacrificed to catabolic activity
such as gluconeogenesis (55,56). All of the case
groups in our study had a negligible difference (P
> 0.05) in total plasma proteins levels. These results
are justifiable when considering that the enhanced
protein degradation associated with diabetes and
starvation is fundamentally different from normal
protein catabolism. In normal eukaryotic cells, large
molecular weight proteins tend to be degraded more
rapidly than small proteins. Acidic proteins tend
to be degraded more rapidly than neutral or basic
proteins, and glycoproteins tend to be degraded
more rapidly than nonglycoproteins. All 3 of these
general correlations are thought to be absent or
markedly reduced in the liver and muscle of diabetic
and starved rats. These results suggest that diabetes
alters the general characteristics of intracellular
protein degradation in the target tissues of insulin.
The degradation of serum proteins is also affected in
cases of diabetes. Under normal conditions, a general
correlation exists between the isoelectric points
of serum proteins and their degradative rates; this
relationship is abolished in diabetes (57).
Nonenzymatic glycation (NEG) is the covalent
binding of reducing sugars to α- or ε-amino groups
on protein (58). Glucose and protein initially form a
labile glycosylamine or Schiff base, the concentration
of which varies with hourly changes in the glucose
concentration. Over time, this intermediate product
undergoes an irreversible Amadori rearrangement
to produce a more stable glycated protein (59,60).
High concentrations of Amadori product indicate
poor diabetic control and are associated with an
increased risk of developing some of the longer-term
complications of the disease (61-63). Quantitative
analysis of these end products could provide a tissue
measure of integrated glycemia over several years

and an estimate of the consequent risk of developing
the above complications. Advanced glycation end
products (AGEs) are found in the retinal vessels of
diabetic patients and their levels correlate with that in
serum as well as with the severity of retinopathy. It is
also known that AGEs accumulate in the peripheral
nerves of diabetic patients and that the use of antiAGE agents improves nerve conduction velocities
and neuronal blood flow abnormalities (64-67).
Averaged NEG plasma concentrations in diabetics
with PDR were higher than those in patients with
NPDR or those without DR, but the difference was
insignificant (P > 0.05). In 2002 and 2004, Tan et al.
(68,69) indicated that diabetic patients had higher
plasma glycation than that of normal subjects (4.24
± 0.88 compared to 3.15 ± 0.81 unit/mL [2002]; 4.6
± 0.7 compared to 3.1 ± 0.8 unit/mL [2004]). Our
results support the findings of Anitha et al. (70), who
investigated the association of the advanced glycation
index (AGI), a simple assay to detect AGEs in serum,
with the severity of DR in type 2 diabetic subjects.
Their findings showed that AGI values increased
with the severity of DR. Among diabetic subjects,
AGI (mean ± SE) was higher among subjects with
nonproliferative diabetic retinopathy (6.7 ± 0.1 U)
and proliferative diabetic retinopathy (9.1 ± 0.3 U)
than among subjects without DR.
These results support the description of diabetes
as a disease characterized by accelerated ocular
complications. Protein glycation may be implicated
in the development of diabetic retinopathy. Intensive
glycemic control by multiple insulin injection
therapy can delay the onset and progression of this
complication, however.
Conclusion
This study demonstrated a high prevalence of DR
in Faisalabad. An organized approach is needed for
adequate prevention and treatment in patients with
diabetes.
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